Grid Therapeutics is an emerging biotechnology company located in Durham, North Carolina. Grid’s research and development efforts are in the area of cancer therapeutics, applying an innovative platform to develop human derived antibodies against novel targets. The Management Team was assembled to rapidly advance these assets to the clinic and have the skillsets and experience to deliver. The Board of Directors has a deep understanding of the current Immuno-Oncology landscape and is poised to help the Management Team deliver an efficient and impactful development plan. The Advisors can give context and insight to a wide range of topics such as clinical practice, groundbreaking lab techniques, and corporate governance.
Edward (Ned) F. Patz Jr. is a co-founder and CEO of Grid Therapeutics. For over 20 years, Dr. Patz has led a basic science laboratory at Duke University focused on lung cancer biology and early cancer detection.
Dr. Patz holds a BS in physics from Duke University, was a researcher in High Energy Physics at Harvard University and received his MD at the University of Maryland. Dr. Patz previously served on the faculty at Brigham and Women’s Hospital, Harvard Medical School, and the Dana-Farber Cancer Institute.
Scott Lyman is the Chief Business Officer at Grid. Mr. Lyman brings nearly 20 years of program management, finance, corporate strategy, and business development expertise to this role. Prior to joining Grid, Mr. Lyman held a diverse range of roles at Amgen, Valeant, Salix, BioCryst, GlaxoSmithKline, and Becton Dickinson.
Mr. Lyman earned a BS, Chemical Engineering from Iowa State University; a MS, Chemical Engineering from the University of Colorado at Boulder; and a MBA. from the University of North Carolina at Chapel Hill.
Thomas L. Patz is the Chief Operating Officer of Grid Therapeutics. Prior to joining Grid, for over twenty years Mr. Patz served as Executive Vice President, Strategic Initiatives, and General Counsel of MICROS Systems, Inc., a publicly traded software company. During his tenure at MICROS, Mr. Patz was instrumental in architecting over 30 transactions, including the sale of MICROS to Oracle Corporation in 2014 for $5.3 Billion.
Mr. Patz holds an AB degree from Brown University and a Juris Doctorate from the University of Virginia School of Law.